Embla Medical hf.
OSSFFOTCHealthcare● Active
$5.11
+$0.96(+23.13%)
Market Cap$2.2B
P/E Ratio—
52W High$5.325
52W Low$4.15
Embla Medical hf. (OSSFF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OSSFF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
$0.03
Est. $0.04 · -17.1%
Revenue
$0.23B
Est. $0.23B · -0.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▼ Miss EPS
OSSFF reports quarterly as a OTC-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 21, 2026 | $0.06 | — | — | — | $0.26B | — |
| ▼ Q2 FY2026 | Apr 28, 2026 | $0.04 | $0.03 | -17.1% | $0.23B | $0.23B | -0.4% |
| ▲ Q1 FY2026 | Feb 3, 2026 | $0.05 | $0.06 | +9.4% | $0.26B | $0.26B | +0.5% |
| — Q3 FY2025 | Jul 22, 2025 | $0.05 | $0.05 | +0.5% | $0.23B | $0.23B | -0.8% |
| ▼ Q2 FY2025 | Apr 29, 2025 | $0.04 | $0.03 | -19.5% | $0.21B | $0.23B | -8.6% |
| ▼ Q1 FY2025 | Feb 5, 2025 | $0.05 | $0.04 | -9.3% | $0.22B | $0.23B | -0.6% |
| ▲ Q4 FY2024 | Oct 22, 2024 | $0.04 | $0.05 | +23.4% | $0.21B | $0.21B | +0.6% |
| ▲ Q3 FY2024 | Jul 23, 2024 | $0.05 | $0.05 | +1.5% | $0.22B | $0.22B | -2.6% |
Q3 FY2026
Jul 21, 2026
EPS Actual
—
EPS Est.
$0.06
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Miss
EPS Actual
$0.03
EPS Est.
$0.04
EPS Surpr.
-17.1%
Revenue
$0.23B
Q1 FY2026
Feb 3, 2026Beat
EPS Actual
$0.06
EPS Est.
$0.05
EPS Surpr.
+9.4%
Revenue
$0.26B
Q3 FY2025
Jul 22, 2025
EPS Actual
$0.05
EPS Est.
$0.05
EPS Surpr.
+0.5%
Revenue
$0.23B
Q2 FY2025
Apr 29, 2025Miss
EPS Actual
$0.03
EPS Est.
$0.04
EPS Surpr.
-19.5%
Revenue
$0.21B
Q1 FY2025
Feb 5, 2025Miss
EPS Actual
$0.04
EPS Est.
$0.05
EPS Surpr.
-9.3%
Revenue
$0.22B
Q4 FY2024
Oct 22, 2024Beat
EPS Actual
$0.05
EPS Est.
$0.04
EPS Surpr.
+23.4%
Revenue
$0.21B
Q3 FY2024
Jul 23, 2024Beat
EPS Actual
$0.05
EPS Est.
$0.05
EPS Surpr.
+1.5%
Revenue
$0.22B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.07 | $0.07 | $0.07 | 1 |
| Q3 FY2026 | $0.07 | $0.07 | $0.07 | 1 |
| Q2 FY2026 | $0.06 | $0.06 | $0.06 | 1 |
| Q1 FY2026 | $0.04 | $0.04 | $0.04 | 1 |
| Q4 FY2025 | $0.05 | $0.05 | $0.06 | 1 |
| Q3 FY2025 | $0.06 | $0.06 | $0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.3B | $0.3B | $0.3B | 2 |
| Q3 FY2026 | $0.3B | $0.3B | $0.3B | 1 |
| Q2 FY2026 | $0.3B | $0.3B | $0.3B | 3 |
| Q1 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
| Q4 FY2025 | $0.3B | $0.3B | $0.3B | 2 |
| Q3 FY2025 | $0.2B | $0.2B | $0.2B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 28, 2026 | -17.1% | $4.15 | $4.15 | +0.00% |
| ▲ Q1 FY2026 | Feb 3, 2026 | +9.4% | $5.04 | $5.04 | +0.00% |
| ▲ Q3 FY2025 | Jul 22, 2025 | +0.5% | $4.15 | $4.15 | +0.00% |
| ▼ Q2 FY2025 | Apr 29, 2025 | -19.5% | $4.15 | $4.15 | +0.00% |
| ▼ Q1 FY2025 | Feb 5, 2025 | -9.3% | $4.77 | $4.77 | +0.00% |
| ▲ Q4 FY2024 | Oct 22, 2024 | +23.4% | $4.81 | $4.81 | +0.00% |
| ▲ Q3 FY2024 | Jul 23, 2024 | +1.5% | $4.27 | $4.25 | -0.47% |
| ▼ Q2 FY2024 | Apr 23, 2024 | -26.9% | No price data | $4.27 | — |
Q2 FY2026+0.00%
Report Date
Apr 28, 2026
EPS Beat/Miss
-17.1%
Price Before
$4.15
Price After
$4.15
Q1 FY2026+0.00%
Report Date
Feb 3, 2026
EPS Beat/Miss
+9.4%
Price Before
$5.04
Price After
$5.04
Q3 FY2025+0.00%
Report Date
Jul 22, 2025
EPS Beat/Miss
+0.5%
Price Before
$4.15
Price After
$4.15
Q2 FY2025+0.00%
Report Date
Apr 29, 2025
EPS Beat/Miss
-19.5%
Price Before
$4.15
Price After
$4.15
Q1 FY2025+0.00%
Report Date
Feb 5, 2025
EPS Beat/Miss
-9.3%
Price Before
$4.77
Price After
$4.77
Q4 FY2024+0.00%
Report Date
Oct 22, 2024
EPS Beat/Miss
+23.4%
Price Before
$4.81
Price After
$4.81
Q3 FY2024-0.47%
Report Date
Jul 23, 2024
EPS Beat/Miss
+1.5%
Price Before
$4.27
Price After
$4.25
Q2 FY2024—
Report Date
Apr 23, 2024
EPS Beat/Miss
-26.9%
Price Before
—
Price After
$4.27
Avg Beat Reaction-0.12%
Avg Miss Reaction+0.00%
Beat Rate4 / 8 quarters
Largest Move-0.47% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OSSFF ends December
Embla Medical hf. (OSSFF) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $0.03 — missing the analyst consensus of $0.04 by -17.1%. The next OSSFF earnings date is expected around September 1, 2026.
Each quarter, investors track OSSFF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OSSFF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OSSFF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OSSFF earnings · 5 questionsEmbla Medical hf.'s next earnings report is expected around September 1, 2026. OSSFF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OSSFF historically reports after market close (AMC).
OSSFF earnings datewhen is OSSFF earningsOSSFF next earnings datewhen does OSSFF report earningsOSSFF earnings calendar
▸ Source: FMP · Embla Medical hf. SEC filings · US GAAP · Embla Medical hf. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026